These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30144422)

  • 1. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
    Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S
    Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
    El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
    Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
    Wang Q; Luo M; Xiang B; Chen S; Ji Y
    Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
    Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
    PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
    Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
    Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
    Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
    Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams PA; Stylianou M; Moss J
    Chest; 2015 Jan; 147(1):180-187. PubMed ID: 25167325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
    El-Chemaly S; Henske EP
    Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
    Bottolo L; Miller S; Johnson SR
    Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
    Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
    Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging biomarkers of lymphangioleiomyomatosis.
    Nijmeh J; El-Chemaly S; Henske EP
    Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.